# Ascentage Pharma Group International share price today (Ascentage Pharma Group International, AAPG)

> Ascentage Pharma Group International's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. AAPG · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/aapg

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $15.13 (−52.3% in a year)
- Revenue (Jun 2026): ₹0.3 B (+29.3% on a year ago)
- Profit (Jun 2026), incl. one-off: −₹0.8 B (one-off item, see below)
- ROE: −93%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Ascentage Pharma Group International share price today? Ascentage Pharma Group International's share price was $15.13 at the close on 5 November 2026. That is 24.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between $14 and $34, and at that close it sat 3% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 31 weeks running. Over the last 1 year the share price moved −60% while the S&P 500 moved +18%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 2 April 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Ascentage Pharma Group International pay? Ascentage Pharma Group International pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Ascentage Pharma Group International on? Ascentage Pharma Group International is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Ascentage Pharma Group International profitable? Ascentage Pharma Group International posted a net loss of ₹0.8 B in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of ₹1.2 B. That loss is 270.2% of the quarter's revenue. The same quarter a year earlier earned ₹0.2 B. 11 of the last 12 reported quarters were loss-making. Read this profit with care: at −₹0.8 B it is bigger than the quarter's whole revenue of ₹0.3 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −248.9% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Ascentage Pharma Group International make, and is it growing? Ascentage Pharma Group International reported ₹0.3 B of revenue in the Jun 2026 quarter, +29.3% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown 113.0% a year on average. The last full year, FY25, came in at ₹0.6 B. FY25 revenue was ₹0.6 B, −41.5% on the year before. Recent pace: the last four quarters grew +43.2% on average, against 113.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −10.9%, against +178.2% a year over the last 8 quarters (rolling over). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Ascentage Pharma Group International keep? Ascentage Pharma Group International has almost no sales yet: FY25 revenue was ₹0.6 B. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is Ascentage Pharma Group International's profit turning into cash? Ascentage Pharma Group International's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹1.2 B of cash, against −₹1.2 B of profit. After ₹0.0 B of spending on assets, free cash was −₹1.2 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Ascentage Pharma Group International's cash go? Ascentage Pharma Group International does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Ascentage Pharma Group International's P/E ratio, and how does it compare with its own history? Ascentage Pharma Group International has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Ascentage Pharma Group International business getting better or worse? Ascentage Pharma Group International's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 10 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Ascentage Pharma Group International earn on its capital? Ascentage Pharma Group International earned a ROE of −93% in FY25. That is up from a low of −1,311% in FY23. Its return on capital used (ROIC) is left out: on sales this small it reads −35%, a number that says nothing useful about the business. ## Does Ascentage Pharma Group International have too much debt? Ascentage Pharma Group International has total debt of ₹2.1 B against shareholder equity of ₹0.6 B as of Jun 2026, so its debt is 3.70× its equity. Year by year, that ratio went from 0.88 in FY21 to 1.48 in FY25. Keep that borrowing in mind when reading the returns on this page. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Ascentage Pharma Group International shareholding pattern? We have no ownership or short-position figures for Ascentage Pharma Group International, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 2.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Ascentage Pharma Group International from balance-sheet trouble? For Ascentage Pharma Group International, the Z-score is −0.14. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −0.14 is inside the danger zone, so the balance sheet is a real risk. ## How does Ascentage Pharma Group International rank in its industry? There is no score against its industry: Ascentage Pharma Group International is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Ascentage Pharma Group International compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Ascentage Pharma Group International in size? Ascentage Pharma Group International is the 96th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Nuvation Bio Inc., Immunocore Holdings plc and uniQure N.V. Just below it: Ocular Therapeutix, Inc., Innoviva, Inc. and AnaptysBio, Inc. ### Biotechnology companies close in size

1. [Nuvation Bio Inc.](https://www.sectoralpha.in/us/stocks/nuvb) $1.5 billion
2. [Immunocore Holdings plc](https://www.sectoralpha.in/us/stocks/imcr) $1.5 billion
3. [uniQure N.V.](https://www.sectoralpha.in/us/stocks/qure) $1.5 billion
4. Ascentage Pharma Group International $1.4 billion
5. [Ocular Therapeutix, Inc.](https://www.sectoralpha.in/us/stocks/ocul) $1.4 billion
6. [Innoviva, Inc.](https://www.sectoralpha.in/us/stocks/inva) $1.4 billion
7. [AnaptysBio, Inc.](https://www.sectoralpha.in/us/stocks/anab) $1.4 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Adecoagro S.A.](https://www.sectoralpha.in/us/stocks/agro) $1.3 billion · Farm Products
2. [U.S. Physical Therapy, Inc.](https://www.sectoralpha.in/us/stocks/usph) $1.3 billion · Medical Care Facilities
3. Ascentage Pharma Group International $1.3 billion
4. [Lucid Group, Inc.](https://www.sectoralpha.in/us/stocks/lcid) $1.3 billion · Auto Manufacturers
5. [Permian Basin Royalty Trust](https://www.sectoralpha.in/us/stocks/pbt) $1.3 billion · Oil & Gas Midstream

## What else do people ask about Ascentage Pharma Group International? ### What were Ascentage Pharma Group International's latest quarterly results? Ascentage Pharma Group International reported revenue of ₹0.3 B and a net loss of ₹0.8 B for the Jun 2026 quarter. The operating margin was −248.9%, 11.8 percentage points lower than a year earlier (as of 5 November 2026). ### What is Ascentage Pharma Group International's market cap? Ascentage Pharma Group International's market capitalisation is $1.4 B at a stock price of $15.13. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Ascentage Pharma Group International performing? Ascentage Pharma Group International's latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 31 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Ascentage Pharma Group International's stock price go up? This page does not forecast Ascentage Pharma Group International's stock price. What it shows instead: the stock price is $15.13. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### What could break the Ascentage Pharma Group International story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Ascentage Pharma Group International a stock worth studying right now? What the numbers show: Ascentage Pharma Group International's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.